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Abstract. A bimetallic heme-DNA cofactor, containing an iron and a copper center, was synthesized for 
the design of novel hybrid catalysts for stereoselective synthesis. The cofactor was used for the 
reconstitution of apo-myoglobin. Both the cofactor alone and its myoglobin adduct were used to catalyze 
a model Diels Alder reaction. Stereoselectivity of this conversion was analyzed by chiral HPLC. 
Reactions carried out in the presence of myoglobin-heme-Cu-DNA catalyst showed greater product 
conversion and stereoselectivity than those carried out with the heme-Cu-DNA cofactor. This observation 
suggested that the protein shell plays a significant role in the catalytic conversion.(doi: 10.5562/cca1828) 
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INTRODUCTION 
One of the ongoing challenges in synthetic chemistry 
concerns the development of powerful catalysts. Of 
particular interest is the use of highly selective and 
efficient enzymes as biocatalysts for chemical synthesis. 
Our increased understanding of chemical and enzymatic 
catalysis has enabled us to explore and develop bio 
inspired catalysts with modified, even enhanced effi-
ciency and selectivity by taking advantage of a variety 
of enzyme classes.1 For example, metalloenzymes, 
which contain a metal ion cofactor as prosthetic group 
are an important class of proteins involved in a range of 
biologically important reactions such as substrate oxida-
tion (cytochrome P450 enzymes, peroxidases),2 carbon 
dioxide fixation (carbonic anhydrase),superoxide dis-
mutation3 and many others. It is estimated that one third 
of all enzymes require a metal cofactor to ensure proper 
function and as a result, numerous studies are devoted to 
the understanding of their structure and function.4 
Owing to the advances in biophysical and computa-
tional chemistry as well as in structural biology, it is no-
wadays possible to design new hybrid metalloenzymes 
with enhanced stability and reaction efficiency. This is 
achieved either by modification of theprotein shell through 
introduction of unnatural amino acids5 or by replacing 
metal containing prosthetic groups with artificial ones.6 
Since tailoring of the protein shell often requires lengthy 
process of site selective mutations and subsequent enzyme 
expression, this approach is often of limited because of the 
low amounts of the biocatalyst that can be produced.5 
On the other hand, the modification of small organ-
ic prosthetic group offers ease of preparation and a range 
of different functions, which can be introduced. By chem-
ical modification of prosthetic groups such as protophor-
phyrin IX (heme) and their insertion into apo-enzymes 
(that are non active enzymes which lack their natural 
prosthetic group), highly efficient catalysts with novel 
properties can be obtained.7 For example, the reconstitu-
tion of apo-myoglobin (apoMb) with ruthenium (II) mod-
ified heme led to the development of photoactivatable 
enzymes, which enable temporal control over oxidation 
reactions catalyzed by myoglobin.8 But the changes in the 
metalloenzyme prosthetic group are not the only ap-
proach to evolve interesting new catalytic properties. 
Introduction of a catalytic moiety into the chiral environ-
ment of a host protein can also lead to novel enantionse-
lective catalysts that are active under mild conditions and 
show high selectivity.9 In one of the first examples, Wil-
son and Whitesides performed enantioselective hydroge-
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nation with avidin as a chiral protein host and biotiny-
lated phosphine rhodium (I) nornborndiene complex as 
the catalytic centre. This approach led to 40 % of enanti-
omeric excess (e.e.) values.10 The initially described 
ligands,10 such as phosphine rhodium complexes were 
later replaced by other metal complexes yielding even 
higher (up to 96 %) e.e. values and increased catalytic 
turnover.9,11 These results clearly indicate that hybrid 
metal-protein complexes hold great potential as catalysts 
in synthetic organic chemistry. Building upon this idea, 
Reetz et al designed hybrid proteins by non-covalent 
attachment of Cu-phtalocyanine to different serum albu-
mins.12 Such proteins were capable of catalyzing Diels 
Alder reaction of azachalcones with cyclopentadiene in 
aqueous medium with high selectivity and e.e. between 
85−93 % depending on the albumins used. Such high e.e. 
clearly indicated the potential of the protein modification 
for design of powerful hybrid catalysts. In the further 
work by the same group, thermostable protein tHIsF was 
modified by site specific mutagenesis to enable Cu2+ 
binding thereby affording an artificial metalloenzyme.13 
The hybrid enzyme achieved 46 % e.e. in Diels Alder 
reaction showing that the rational introduction of catalytic 
groups to the natural proteins can lead to a design of 
novel catalysts, however some issues of site directed 
mutagenesis and catalytic selectivity need to be resolved. 
Recently, DNA has also been used as a chiral sup-
port for enantioselective catalysts because of its chemical 
stability and well defined structure.14,15 In addition, DNA 
from natural sources such as salmon sperm or calf thy-
mus, can be obtained in relatively large quantities com-
pared to the proteins. DNA could also enable rational 
design of the desired catalytic centre as numerous metal 
binding functional groups with huge catalytic potential 
can be introduced to the natural systems. As an example, 
taking advantage of the ability of certain functional 
groups to intercalate the double-stranded DNA, Roelfes 
et al. designed Cu2+ complex which, when bound to the 
DNA, revealed good enantioselectivity in Diels Alder 
reaction.14a,14b Similar hybrid catalytic systems based on 
DNA and Cu complexes were also used for other reac-
tions such as Friedel Crafts alkylation16 and Michael 
addition.17 In previous work we have shown that func-
tional DNA-heme protein conjugates as well as photoac-
tivatable enzymes can be generated by reconstitution of 
apoMb with chemically modified heme derivatives.18 
Motivated by the aforementioned developments of hybrid 
metalloenzyme catalysts, we here demonstrate for the 
first time that the reconstitution of apoMb with a bimetal-
lic heme cofactor can be used to create novel catalysts for 
stereoselective synthesis. In particular, we report on the 
synthesis of an artificial heme group containing a single-
stranded DNA oligonucleotide as well as an appended Cu 
(II) moiety, which was successfully used for reconstitu-
tion of apoMb. The resulting hybrid was used as a cata-
lyst in a model Diels-Alder reaction revealing moderate 
stereoselectivity as a consequence of the chiral environ-
ment provided by both the DNA and protein shell. 
 
RESULTS AND DISCUSSION 
Modification of heme moiety and its reconstitution into 
apo enzymes has been successfully used as a tool for 
introducing new functionalities to the heme enzymes.6 
In such way novel biomaterials were designed by use of 
DNA-19 and polymer modified heme groups.20 In many 
cases, enhanced catalytic performance was enabled by 
modification of the heme propionate groups,21 exchange 
of iron centre22 or by appending electro-23 and photo-
active8,24 groups to these side chains. Inspired by the 
work of Hamachi et al.24 on photoactivatable Mb, we 
have previously synthesized tris (2, 2’-bipyridyl)ruthe-
nium (II) Ru(bpy)32+-DNA heme conjugate, in which 
the Ru moiety is used for the photoactivation of the 
artificial catalyst while the DNA moiety can be har-
nessed for selective hybridization-based immobiliza-
tion.18 Herewith we show that a similar synthetic route 
can be used to synthesize a heme derivative chemically 
modified with a Cu(bpy)2+ moiety to provide active 
centre for the catalysis of Diels-Alder reaction. 
5’ alkylamino modified oligonucleotide 1, which 
remained bound on the controlled pore glass (CPG) sup-
port after solid-phase phosphoamidite synthesis was re-
acted with heme in the presence of HBTU/HOBt/DIPEA 
(HBTU=O-benzotriazole-N,N’,N’’-tetramethyl-uronium 
hexafluorophosphate, HOBt= 1-hydroxybenzotriazole, 
DIEA = diisopropylethylamine) as activating agents for 
amide coupling.6 As a result, two products are formed, 
namely heme derivatives where one or both propionic 
groups are modified with a DNA strand (2 and 3 respec-
tively in Figure 1). 
Figure 1. Schematic representation of the Byp-heme-DNA
synthesis using solid phase synthetic procedure. 
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The CPG was then washed and reacted with an 
access of amino-bpy 4, synthesized according to a pre-
viously reported procedure, to yield heme derivative 5 
(Figure 1). Subsequent to the cleavage from the CPG 
support using t-butylamine/meOH/water treatment at  
65 °C, the crude reaction mixture was analyzed and 
purified by high performance liquid chromatography 
(HPLC). Besides the unreacted DNA (1) and the bypro-
duct HemeD2 (3), the desired bpy-hemeD1 (5) complex 
was obtained(Figure 2). The reaction yield was about  
10 % with respect to the used amount of DNA, which is 
in good agreement with earlier studies.18 
In addition to HPLC characterization, the presence 
of the expected product 5 was also confirmed by MAL-
DI-MS analysis (Figure S1), which revealed an ob-
served mass peak at m/z = 7937, corresponding to 
[M+NH4]+. Byp-hemeD1 5 was then incubated with 10 
equivalents of Cu(NO3)2 to afford Cu(byp)2+-hemeD1 6 
(Figure 3a) and the product was purified by gel filtration 
chromatography to remove excess of the inorganic salt. 
MALDI-MS analysis indicated complete conversion 
(peak at m/z = 7983, corresponding to [M+2H]+ (Figure 
3b). 
To investigate the effect of the DNA strand on the 
enantioselective catalysis, Cu(byp)-hemeD1 was hybri-
dized with its complementary strand to form double 
stranded, chiral conjugate Cu(byp)-hemeD1cD1 7 (Fig-
ure 4a). The hybrid was then used as the catalyst for 
Diels Alder reaction between dienophile 3-phenyl-1-(2-
pyridyl)-2-propen-1-one 8 and cyclopentadiene 9, which 
was previously shown to be catalyzed by Cu2+.25 Dieno-
phile 8 was prepared by aldol condensation of benzal-
dehyde with a slight excess of 2-acetylpyridine at 0 °C 
in water, as previously reported.26 
Since 8 is a poor dienophile, Diels Alder reaction 
only occurs in the presence of Lewis acids.25a In a test 
reaction, compound 8 was first reacted with 9 in pres-
ence of Cu(NO3)2 salt to afford a racemic mixture of 
endo (major compund 10 a and b) and exo (minor, 
compound 11a and b) isomers (Figure S2). Chiral 
HPLC analysis of the reaction products revealed that 
four major products were formed, corresponding to the 
exo (11) and endo isomers (10). The endo/exo ratio was 
11.4 and, as expected, no e.e. was observed. The reten-
tion times of the product peaks were comparable to 
those of the products of the previously studied Lewis 
acid catalyzed enantioselective Diels Alder reaction.14b 
These data were used as a reference for the expe-
riments using Cu(byp)-hemeD1cD1 conjugate 7 as the 
catalyst (Figure 4b). Conjugate 7 was obtained from 6 
by simple hybridization with one molar equivalent of 
the complementary ssDNA oligonucleotide. Subsequent 
to the incubation of the dienophile and diene for 72 
hours at 4 °C in the presence of hybrid 7, the reaction 
mixture was analyzed by chiral HPLC. Remarkably, the 
analysis revealed only two peaks corresponding to the 
endo adducts, while no exo adduct could be detected 
(Figure 4c). However, calculation of the product con-
version based on the corresponding peak areas showed 
that the products were only formed in about 6 % yield. 
Chiral HPLC analysis also revealed that no enantiomer-
ic excess was obtained in the reaction catalyzed by 
hybrid 7. This might be explained by the fact that the 
chiral microenvironment of the dsDNA is too far away 
from the copper centre. 
Figure 2. Chromatogram of HPLC analysis of modified heme
purification after cleavage and deprotection from CPG solid
support. 
Figure 3. Preparation a) and identification b) of Cu(II)byp-
heme-D1 6 conjugate. 
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To explore further the effect of biomolecular envi-
ronment on the stereoselectivity of the catalytic Cu 
centre, conjugate 6 was used to reconstitute apoMb 
(Figure 5a), thereby enabling the investigation of poten-
tial effects of chiral protein shell. It was expected that 
the second coordination sphere created by the protein 
shell should influence the Cu2+ catalyzed Diels Alder 
reaction since the catalytic metal centre is closely em-
bedded in the chiral microenvironment provided by the 
protein and ssDNA moieties. 
After reconstitution of apoMb with conjugate 6, 
the reaction mixture was analyzed and purified by FPLC 
using an anion exchange column (Figure 5b). The re-
sulting Cu(byp)-Mb-D1 conjugate 12 (0.1 mmol dm−3) 
was then used as catalyst for Diels Alder reaction under 
same conditions as described above. The reaction mix-
ture was subjected to the chiral HPLC analysis (Figure 
5c). Peaks 11a and 11b refer to the both enantiomers of 
exo product and peaks 10 a, b correspond to both enan-
tiomers of the endo product, while peaks 8 and 9 cor-
respond to the educts. The product conversion of about 
71 % was significantly higher than observed for the 
DNA hybrid catalyst 7. The endo/exo selectivity (8.6) 
was lower than observed for 7, however distinctive 
enantioselectivity could be observed with e.e. values for 
endo product of 18 % and for exo products of 10 %. 
These results illustrate that the semisynthetic en-
zyme 12 is a far better catalyst than Cu(byp)-
hemeD1cD1 7. Higher product conversion and greater 
enantioselectivity suggest that the protein shell plays a 
significant role in the overall catalytic effect. Indeed, the 
catalytic copper centre is closer to the chiral microen-
vrionment of the myoglobin. In comparison with pre-
viously studied systems of DNA-metal catalytic hybrids 
 
Figure 4. Hybridisation of hemeD1 6 with complementary DNA strand to afford double stranded conjugate 7 (a), which is then
used as a catalyst for Diels Alder reaction (b). Chiral HPLC analysis of Diels Alder adducts catalysed by heme-D1cD 7 conjugate. 
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for similar Diels Alder reactions,14 however, our semi-
synthetic protein conjugate were less efficient with 
respect to the enantioselectivity. Therefore, further work 
will focus on exploring other protein models where the 
Cu centre is more closely embedded in the protein shell. 
Moreover, different porphyrins and DNA sequences 
will be investigated to generate a library of semisynthet-
ic enzyme-DNA catalysts. 
 
Figure 5. Reconstitution of heme 6 into apo myoglobin to prepare hybrid catalyst 12 (a) and subsequent FPLC purification. Diels
Alder reaction products were analysed by chiral HPLC (c). 
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EXPERIMENTAL SECTION 
Copper ligand 4: amno-Bpy 4 was synthesized using 
modified approach described previously by Hamachi8 
and Kuo.18 Detailed experimental procedures are pro-
vided in the Supporting Information 
Preparation of bpy-hemeD1 conjugate 5. Commer-
cially available amino modified oligonucleotide (5’Tr-
amino-GTG GAA AGT GGC AAT CGT GAA G), 
which was still coupled to the CPG support and con-
tained the protection group. The trityl group was ma-
nually removed using commercial 3 % dichloroacetic 
acid (DCA) in dichloromethane solution followed by 
washing with CH3CN and drying with argon. Hemin  
(75 μmol) and HBTU (75 μmol) were dissolved in 1.0 
ml DMF and to this HOBt (50 μmol) in 500 μL CH3CN 
was added followed by 27 μL DiPEA. This solution was 
mixed with the detritylated oligonucleotide and coupl-
ing was allowed to proceed for 180 minutes at 20 °C. 
The resulting CPG suspension was then washed tho-
roughly with DMF and CH3CN and dried with argon. 
HOBt (50 μmol) and HBTU (75 μmol) were dissolved 
in 1.0 ml DMF and to this aminoalkyl-modified bipyri-
dine, amino-Bpy 4 (75 μmol) in 500 μL CH3CN was 
added followed by 27 μL DiPEA. This solution was 
then incubated at 40 °C overnight. The modified oligo-
nucleotide was then de-protected using t-butyla-
mine:MeOH:H2O (1:2:1) mixture for 3 h at 65 °C, puri-
fied by HPLC and analyzed by MALDI-TOF mass 
spectrometry. 
Preparation of BpyCu-hemeD1 conjugate 6:  
0.1 mmol dm−3 of bpy-hemeD1 conjugate 5 was incu-
bated in a 1 mmol dm−3 aqueous solution of Cu(NO3)2 at 
room temperature for 3 hours, to yield Cu(bpy)2+-heme-
DNA conjugate. The product was successively purified 
with NAP 5, NAP 10 columns and Vivaspin® columns 
(cutoff filter 5000) in order to remove the excess of 
inorganic salts thoroughly. The conjugate was then 
analyzed with MALDI-TOF mass spectrometry. 
Reconstitution of apo-myoglobin with artificial co-
factor. Apo-myoglobin (aMb) was prepared by Teale’s 
2-butanone method. In brief, the aqueous myoglobin 
solution was acidified by adding pre-cooled diluted 
hydrochloric acid (0.1 M HCl(aq), 4 °C) and the pH value 
was adjusted to 2.5−3.0 in order to denature myoglobin 
and thus to enable the release of heme. Heme was ex-
tracted from the aqueous solution by 2-butanone. The 
heme / 2-butanone solution was discarded and the a-
queous apo-myoglobin solution was then purified using 
NAP columns in order to remove remaining 2-butanone 
and re-buffered in phosphate buffer (Kpi, pH 7.4) 
meanwhile. The protein concentration was determined 
spectrometrically by molar extinction coefficient of apo-
myoglobin at 280 nm (ε280 = 15800 cm−1 mol−1 dm3). A 
solution of the apo-enzyme (200 L, 60 mol dm−3) in 
potassium phosphate buffer, pH 7, was then mixed with 
BpyCu-hemeD1 6 conjugate (1.1 equiv., 330 L, 40 
mol dm−3) and incubated for at least 24 hours at 4 °C. 
Reconstituted enzymes were purified using ion ex-
change FPLC (AKTA purifier, Amersham Bioscience, 
MonoQ column, buffer A: 20 mmol dm−3 Tris A pH 8.3 
and buffer B: 20 mmol dm−3 Tris A and 1.5M NaCl 
using stepwise gradient (saved method: CHKHemen-
zyme.m01). The concentration of reconstituted myoglo-
bin was determined spectrometrically by molar extinc-
tion coefficient of Soret band at 405 nm (ε405 = 171000 
cm−1 mol−1 dm3). 
Enantioselective catalytic reaction. An 1 mL of 
aqueous solution containing freshly distilled [cyclopen-
tadiene 9] = 15 mmol dm−3, [aza-chalcone 8] = 1 mmol 
dm−3, [catalytic conjugate] = 0.1 mmol dm−3 in phos-
phate buffer (pH 7.4) was incubated under orbital shak-
ing for 72 hours. The resulting reaction mixtures were 
then extracted with diethyl ether and were subjected to 
chiral-HPLC analysis (Daicel ODH, Hexane/IPA = 80 / 
20, flow rate: 0.9 mL/min). The retention time of the 
products in the chiral-HPLC analysis was assigned 
according to the previously. The exo-isomers appeared 
at the retention time of 7.1 and 7.5 minutes while the 
endo-isomers appeared at the retention time of 8.1 and 
9.2 minutes. The enantiomeric excess was estimated 
from the peak area in the chiral-HPLC chromatogram. 
The product conversion was estimated from the peak 










Where area P is the total peak area of the product of the 
reaction, area S is the peak area of the starting material 
and c is the correction factor determined to be 1.21. 
Supplementary Materials. Supporting informations to the 
paper are enclosed to the electronic version of the article. 
These data can be found on the website of Croatica Chemica 
Acta (http://public.carnet.hr/ccacaa). 
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